G. B. John Mancini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
G. B. John Mancini has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
Robert A. Hegele
10 shared publicationsArnold Ryomoto
Cardiovascular Imaging Core Laboratory, Centre for Cardiovascular Innovation, Dilawri Cardiovascular Institute, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
9 shared publicationsJacques Genest
Research Institute of the McGill University Health Center, Department of Medicine, Montreal, Quebec, Canada
8 shared publicationsLawrence A. Leiter
Division of Endocrinology and Metabolism, St Michael's Hospital-Unity Health Toronto, Department of Medicine, Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
7 shared publicationsWilliam E. Boden
Division of Cardiology, Department of Medicine, VA New England Healthcare System; Boston University School of Medicine, Boston, Massachusetts
7 shared publicationsPamela M. Hartigan
Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Temporal changes in lipoprotein(a) following acute coronary syndrome: a systematic review and meta-analysis
Aims: Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual’s lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS. Methods and results: This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after an index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed. Of 3811 records, 16 studies comprising 1396 patients met the inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 h post-ACS (+2.5%, 95% confidence interval [CI] −6.8 to 11.7; P = 0.602). Lp(a) was significantly higher at 7–14 days (+44.0%, 95% CI 4.0–84.1; P = 0.031), 1 month (+28.3%, 95% CI 2.7–54.0; P = 0.030), and 3–6 months (+22.2%, 95% CI 2.4–42.0; P = 0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. Conclusion: Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.
- 11 November 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessTemporal changes in lipoprotein(a) following acute coronary syndrome: a systematic review and meta-analysis
Aims: Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual’s lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS. Methods and results: This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after an index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed. Of 3811 records, 16 studies comprising 1396 patients met the inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 h post-ACS (+2.5%, 95% confidence interval [CI] −6.8 to 11.7; P = 0.602). Lp(a) was significantly higher at 7–14 days (+44.0%, 95% CI 4.0–84.1; P = 0.031), 1 month (+28.3%, 95% CI 2.7–54.0; P = 0.030), and 3–6 months (+22.2%, 95% CI 2.4–42.0; P = 0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. Conclusion: Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.
- Open Access
- 26 August 2026
- Published by Elsevier in Canadian Journal of Cardiology
Viewpoint: Which Patient Is a VESALIUS-CV Patient? Rethinking Primary and Secondary Prevention
- 26 August 2026
- Published by Elsevier in Canadian Journal of Cardiology
Open AccessViewpoint: Which Patient Is a VESALIUS-CV Patient? Rethinking Primary and Secondary Prevention
- Open Access
- 19 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9) , 103162
Effect of Evolocumab on Grafts Post-Coronary Artery Bypass Surgery
- 19 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9) , 103162
Open AccessEffect of Evolocumab on Grafts Post-Coronary Artery Bypass Surgery
- Open Access
Using Pragmatic Research Methods to Address a Global Pandemic: Lessons Learned from NACMI
The COVID-19 pandemic presented a unique opportunity for researchers to use pragmatic methods to obtain information about the virus and promptly disseminate the findings for healthcare providers to utilize them. One such approach to studying patients who presented with COVID-19 and ST-Elevation Myocardial Infarction (STEMI) was the development of the North American COVID-19 STEMI (NACMI) registry. By leveraging social media and communication platforms such as WhatsApp, cardiologists across North America initiated the development of the NACMI registry within 14 days—an accomplishment which was unfathomable pre-pandemic. This was followed by ethics approval through a centralized Institutional Review Board, which led to patient consent being waived, and the use of a single coordinating center (Minneapolis Heart Institute Foundation) responsible for sites, database, and analysis. The NACMI findings were published rapidly across various media, including high-profile cardiovascular journals. Early results demonstrated an elevated mortality rate, disproportionality based on race, and angiographic differences showing unique mechanistic differences in the etiology of STEMI due to COVID-19. Additionally, NACMI provided early evidence that vaccination for COVID-19 reduced the risk of mortality in those with COVID-19 and STEMI. NACMI provided a framework for informing cardiologists early on regarding the optimal treatment of STEMI in patients with COVID-19. The lessons learned may be valuable for developing policy in future pandemics to treat patients using real-world application and routinely collected variables.
Open AccessUsing Pragmatic Research Methods to Address a Global Pandemic: Lessons Learned from NACMI
The COVID-19 pandemic presented a unique opportunity for researchers to use pragmatic methods to obtain information about the virus and promptly disseminate the findings for healthcare providers to utilize them. One such approach to studying patients who presented with COVID-19 and ST-Elevation Myocardial Infarction (STEMI) was the development of the North American COVID-19 STEMI (NACMI) registry. By leveraging social media and communication platforms such as WhatsApp, cardiologists across North America initiated the development of the NACMI registry within 14 days—an accomplishment which was unfathomable pre-pandemic. This was followed by ethics approval through a centralized Institutional Review Board, which led to patient consent being waived, and the use of a single coordinating center (Minneapolis Heart Institute Foundation) responsible for sites, database, and analysis. The NACMI findings were published rapidly across various media, including high-profile cardiovascular journals. Early results demonstrated an elevated mortality rate, disproportionality based on race, and angiographic differences showing unique mechanistic differences in the etiology of STEMI due to COVID-19. Additionally, NACMI provided early evidence that vaccination for COVID-19 reduced the risk of mortality in those with COVID-19 and STEMI. NACMI provided a framework for informing cardiologists early on regarding the optimal treatment of STEMI in patients with COVID-19. The lessons learned may be valuable for developing policy in future pandemics to treat patients using real-world application and routinely collected variables.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e047897
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid
Background: Lowering low‐density lipoprotein cholesterol (LDL‐C) reduces the risk of major vascular events across all age groups. We analyzed phase 3 studies of bempedoic acid to characterize the safety and efficacy in patients aged ≥75 years with and without a concomitant statin. Methods: Post hoc analysis of bempedoic acid in high‐risk patients with cardiovascular disease by age from phase 3 placebo‐controlled, randomized clinical trials: two 52‐week primary hyperlipidemia studies with maximal background statin (“max‐statins pool”), and 1 cardiovascular outcomes trial (“statin‐intolerant pool”). Efficacy (LDL‐C, non–high‐density lipoprotein cholesterol, total cholesterol, high‐sensitivity C‐reactive protein) and safety were evaluated. Results: The max‐statins pool included 3009 (2010 bempedoic acid, 999 placebo) patients. The statin‐intolerant pool included 13 970 patients (6992 bempedoic acid, 6978 placebo). In total 7022 patients were aged 18 to <65 years; 7372 were aged 65 to <75 years; 2585 were aged ≥75 years. Placebo‐corrected mean percentage change in LDL‐C at week 12 in the max‐statin pool with bempedoic acid was −18.4% (95% CI, −21.3 to −15.6) for patients aged 18 to <65 years, −18.6% (95% CI, −21.2 to −16.1) for 65 to <75 years, and −18.3% (95% CI, −22.2 to −14.5) for ≥75 years. In the statin‐intolerant pool, LDL‐C change was −21.9% (95% CI, −23.1 to −20.7) for patients aged 18 to <65 years, −22.9% (95% CI, −24.0 to −21.8) for 65 to <75 years, and −24.5% (95% CI, −26.2 to −22.7) for ≥75 years. Frequency of adverse events compared with placebo was similar across the ages, but more frequent among patients ≥75 years regardless of background statin. Cardiovascular event reduction was statistically comparable across all ages. Conclusions: Bempedoic acid was well tolerated in patients aged ≥75 years with efficacy and safety comparable with younger subgroups regardless of background statin usage. Bempedoic acid may be considered a viable strategy for managing hypercholesterolemia in adults, regardless of age.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e047897
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid
Background: Lowering low‐density lipoprotein cholesterol (LDL‐C) reduces the risk of major vascular events across all age groups. We analyzed phase 3 studies of bempedoic acid to characterize the safety and efficacy in patients aged ≥75 years with and without a concomitant statin. Methods: Post hoc analysis of bempedoic acid in high‐risk patients with cardiovascular disease by age from phase 3 placebo‐controlled, randomized clinical trials: two 52‐week primary hyperlipidemia studies with maximal background statin (“max‐statins pool”), and 1 cardiovascular outcomes trial (“statin‐intolerant pool”). Efficacy (LDL‐C, non–high‐density lipoprotein cholesterol, total cholesterol, high‐sensitivity C‐reactive protein) and safety were evaluated. Results: The max‐statins pool included 3009 (2010 bempedoic acid, 999 placebo) patients. The statin‐intolerant pool included 13 970 patients (6992 bempedoic acid, 6978 placebo). In total 7022 patients were aged 18 to <65 years; 7372 were aged 65 to <75 years; 2585 were aged ≥75 years. Placebo‐corrected mean percentage change in LDL‐C at week 12 in the max‐statin pool with bempedoic acid was −18.4% (95% CI, −21.3 to −15.6) for patients aged 18 to <65 years, −18.6% (95% CI, −21.2 to −16.1) for 65 to <75 years, and −18.3% (95% CI, −22.2 to −14.5) for ≥75 years. In the statin‐intolerant pool, LDL‐C change was −21.9% (95% CI, −23.1 to −20.7) for patients aged 18 to <65 years, −22.9% (95% CI, −24.0 to −21.8) for 65 to <75 years, and −24.5% (95% CI, −26.2 to −22.7) for ≥75 years. Frequency of adverse events compared with placebo was similar across the ages, but more frequent among patients ≥75 years regardless of background statin. Cardiovascular event reduction was statistically comparable across all ages. Conclusions: Bempedoic acid was well tolerated in patients aged ≥75 years with efficacy and safety comparable with younger subgroups regardless of background statin usage. Bempedoic acid may be considered a viable strategy for managing hypercholesterolemia in adults, regardless of age.
- Open Access
- 24 April 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8)
Persistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes From the NACMI Registry
- 24 April 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8)
Open AccessPersistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes From the NACMI Registry
- Open Access
- 18 March 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (4) , 383-390
Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis
1. Patients with dialysis-dependent chronic kidney disease (CKD) have an extremely high cardiovascular (CV) burden, with CV mortality rates 10 to 20 times higher than the general population [1,2]. ...
- 18 March 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (4) , 383-390
Open AccessOmega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis
1. Patients with dialysis-dependent chronic kidney disease (CKD) have an extremely high cardiovascular (CV) burden, with CV mortality rates 10 to 20 times higher than the general population [1,2]. ...